RxDoctor Payments Data

Luis Caceres, MD

Cardiovascular Disease · Decatur, ILNPI 1942381496

Payments from drug & device makers

$7,889in general payments, 2019–2025

Across 129 payments — averaging $61.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$7K
  • Novartis$564
  • Pfizer$120
  • Cook Medical LLC$106
  • Johnson & Johnson$97
  • Philips North America LLC$57
  • plus $223 from 7 others

What the payments were for

  • Consulting fees$3705%
  • Travel & lodging$4,70360%
  • Food & beverage$2,75735%
  • Education$601%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,889 in reported general payments places this provider in the 75th percentile of 932 cardiovascular disease providers in Illinois.

See all cardiovascular disease providers in Illinois

Medicare billing

Part B allowed, 2024
$456,652
Medicare patients
1,590
Services billed
6,125

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban520$419,267
EntrestoSacubitril/Valsartan224$192,877
XareltoRivaroxaban172$137,400
MultaqDronedarone Hcl13$29,166
JardianceEmpagliflozin35$26,442
Repatha SureclickEvolocumab41$26,142
Praluent PenAlirocumab26$17,750
BrilintaTicagrelor22$12,063
FarxigaDapagliflozin Propanediol11$8,228
Metoprolol Succinate488$6,789
Dabigatran EtexilateDabigatran Etexilate Mesylate19$5,476
Atorvastatin Calcium462$4,116
Diltiazem 24hr Er (Cd)Diltiazem Hcl152$3,199
Ezetimibe72$2,741
Metoprolol Tartrate438$2,731

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$120$419,267520 claims
NovartisEntresto$564$192,877224 claims
Johnson & JohnsonXarelto$97$137,400172 claims
AstraZenecaBrilinta, Farxiga$31$20,29133 claims
Mylan Inc.Atorvastatin Calcium$34$4,116462 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 932 cardiovascular disease providers in Illinois.

Other cardiovascular disease in Decatur

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →